Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,829 Lymphoma
clinical trials

Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fargo, ND
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fargo, ND
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fosston, MN
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Franklin, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Grenada, MS
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Harrison, NY
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Longview, WA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Marlette, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Martinsburg, WV
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Martinsville, VA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Melrose Park, IL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Nampa, ID
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Oxford, MS
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Perrysburg, OH
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Pontiac, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Pontiac, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Sacramento, CA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saginaw, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Torrington, CT
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Waukesha, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
York, PA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Harrison, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Commack, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Boise, ID
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Project: Every Child for Younger Patients With Cancer
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Charleston, WV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Project: Every Child for Younger Patients With Cancer
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Fargo, ND
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Project: Every Child for Younger Patients With Cancer
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Project: Every Child for Younger Patients With Cancer
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Miami, FL
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Commack, NY
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Darlinghurst,
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Wurzburg,
Click here to add this to my saved trials
Neurology, Oncology Clinical Trial
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Commack, NY
Click here to add this to my saved trials
Lymphangioleiomyomatosis Clinical Trial
Safety and Durability of Sirolimus for Treatment of LAM
Status: Enrolling, Phase
Updated: 4/10/2018
mi
from
Houston, TX
Click here to add this to my saved trials
Primary Mediastinal B-cell Lymphoma Clinical Trial
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Buenos Aires,
Click here to add this to my saved trials
Follicular Lymphoma Clinical Trial
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 11/2/2015
mi
from
Charleston, WV
Click here to add this to my saved trials
Follicular Lymphoma Clinical Trial
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 11/2/2015
mi
from
Novi, MI
Click here to add this to my saved trials
Follicular Lymphoma Clinical Trial
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 11/2/2015
mi
from
Orange, CA
Click here to add this to my saved trials
Lymphoma,Non-Hodgkin Clinical Trial
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Danville, PA
Click here to add this to my saved trials
Lymphoma,Non-Hodgkin Clinical Trial
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lymphoma,Non-Hodgkin Clinical Trial
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Rockville Center, NY
Click here to add this to my saved trials
Lymphoma,Non-Hodgkin Clinical Trial
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Watertown, SD
Click here to add this to my saved trials
Lymphoma,Non-Hodgkin Clinical Trial
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
West Covina, CA
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Memphis, TN
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
North Ryde,
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Cutaneous T-Cell Lymphoma Clinical Trial
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Miami, FL
Click here to add this to my saved trials
Cutaneous T-Cell Lymphoma Clinical Trial
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hodgkin's Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Status: Enrolling, Phase II
Updated: 3/3/2016
mi
from
Boston, MA
Click here to add this to my saved trials
Hodgkin's Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Status: Enrolling, Phase II
Updated: 3/3/2016
mi
from
Duarte, CA
Click here to add this to my saved trials
Hodgkin's Lymphoma Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Status: Enrolling, Phase II
Updated: 3/3/2016
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Nashville, TN
Click here to add this to my saved trials
Relapsed/Refractory Mantle Cell Lymphoma Clinical Trial
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Denver, CO
Click here to add this to my saved trials
Lymphoma, Non-Hodgkin Clinical Trial
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Enrolling, Phase III
Updated: 12/31/1969
mi
from
La Jolla, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Detroit, MI
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Yvoir,
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Decatur, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Harvey, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Maywood, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Newport News, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Enrolling, Phase II, III
Updated: 12/31/1969
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Expanded Access Protocol for Tabelecleucel in Subjects With EBV-Associated Viremia or Malignancies
Status: Enrolling, Phase
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma Clinical Trial
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Enrolling, Phase I
Updated: 12/31/1969
mi
from
Hospitalet de Llobregat,
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Fairfax, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
mi
from
Greenville, SC
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
Status: Enrolling, Phase II
Updated: 9/11/2017
mi
from
Rochester, MN
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Status: Enrolling, Phase I
Updated: 4/11/2016
mi
from
St. Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
BTK Inhibitor in B Cell Malignancies
Status: Enrolling, Phase I, II
Updated: 11/22/2016
mi
from
Darmstadt,
Click here to add this to my saved trials
Immunology / Infectious Diseases, Oncology Clinical Trial
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Downey, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Gainesville, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Enrolling, Phase II
Updated: 12/31/1969
mi
from
Mineola, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Clayton,
Click here to add this to my saved trials
Oncology Clinical Trial
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Status: Enrolling, Phase I, II
Updated: 12/31/1969
mi
from
Houston, TX
Click here to add this to my saved trials
1 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98